Antiretroviral Neuropenetration Scores Better Correlate with Cognitive Performance of HIV-Infected Patients after Accounting for drug Susceptibility

d'Arminio Monforte A. , Cinque P. , Mocroft A. Changing incidence of central nervous system diseases in the EuroSIDA cohort. Ann Neurol 2004; 55: 320–328.

Robertson K.R. , Smurzynski M. , Parsons T.D. The prevalence and incidence of neurocognitive impairment in the HAART era. AIDS 2007; 21: 1915–1921.

Simioni S. , Cavassini M. , Annoni J.M. Cognitive dysfunction in HIV patients despite long-standing suppression of viremia. AIDS 2010; 24: 1243–1250.

Heaton R.K. , Franklin D.R. , Ellis R.J. HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors. J Neurovirol 2011; 17: 3–16.

Antiretroviral Therapy Cohort Collaboration. Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Lancet 2008; 372: 293–299.

Ciccarelli N, Fabbiani M, Grima P, et al. Comparison of cognitive performance in HIV or HCV mono-infected and HIV-HCV co-infected patients. Infection 2013; 41: 1103–1109.

Fabbiani M. , Ciccarelli N. , Tana M. Cardiovascular risk factors and carotid intima-media thickness are associated with lower cognitive performance in HIV-infected patients. HIV Med 2013; 14: 136–144.

Grima P. , Fabbiani M. , Ciccarelli N. Increased ophthalmic artery resistance index is associated with cognitive impairment in HIV-infected patients. J Infect 2012; 65: 439–446.

Lovejoy T.I. , Suhr J.A. The relationship between neuropsychological functioning and HAART adherence in HIV-positive adults: a systematic review. J Behav Med 2009; 32: 389–405.

Ciccarelli N. , Fabbiani M. , Di Giambenedetto S. Efavirenz associated with cognitive disorders in otherwise asymptomatic HIV-infected patients. Neurology 2011; 76: 1403–1409.

Letendre S. , Marquie-Beck J. , Capparelli E. Validation of the CNS Penetration-Effectiveness rank for quantifying antiretroviral penetration into the central nervous system. Arch Neurol 2008; 65: 65–70.

Letendre S. Central nervous system complications in HIV disease: HIV-associated neurocognitive disorder. Top Antivir Med 2011; 19: 137–142.

Cysique L.A. , Vaida F. , Letendre S. Dynamics of cognitive change in impaired HIV-positive patients initiating antiretroviral therapy. Neurology 2009; 73: 342–348.

Tozzi V. , Balestra P. , Salvatori M.F. Changes in cognition during antiretroviral therapy: comparison of 2 different ranking systems to measure antiretroviral drug efficacy on HIV-associated neurocognitive disorders. J Acquir Immune Defic Syndr 2009; 52: 56–63.

Smurzynski M. , Wu K. , Letendre S. Effects of central nervous system antiretroviral penetration on cognitive functioning in the ALLRT cohort. AIDS 2011; 25: 357–365.

Ciccarelli N. , Fabbiani M. , Colafigli M. Revised central nervous system neuropenetration-effectiveness score is associated with cognitive disorders in HIV-infected patients with controlled plasma viraemia. Antivir Ther 2013; 18: 153–160.

Marra C.M. , Zhao Y. , Clifford D.B. Impact of combination antiretroviral therapy on cerebrospinal fluid HIV RNA and neurocognitive performance. AIDS 2009; 23: 1359–1366.

Kahouadji Y. , Dumurgier J. , Sellier P. Cognitive function after several years of antiretroviral therapy with stable central nervous system penetration score. HIV Med 2013; 14: 311–315.

Caniglia E.C. , Cain L.E. , Justice A. Antiretroviral penetration into the CNS and incidence of AIDS-defining neurologic conditions. Neurology 2014; 83: 134–141.

Garvey L. , Surendrakumar V. , Winston A. Low rates of neurocognitive impairment are observed in neuro-asymptomatic HIV-infected subjects on effective antiretroviral therapy. HIV Clin Trials 2011; 12: 333–338.

Ciccarelli N. , Fabbiani M. , Baldonero E. Effect of aging and human immunodeficiency virus infection on cognitive abilities. J Am Geriatr Soc 2012; 60: 2048–2055.

Bartels C. , Wegrzyn M. , Wiedl A. , Ackermann V. , Ehrenreich H. Practice effects in healthy adults: a longitudinal study on frequent repetitive cognitive testing. BMC Neurosci 2010; 11: 118.

Antinori A. , Arendt G. , Becker J.T. Updated research nosology for HIV-associated neurocognitive disorders. Neurology 2007; 69: 1789–1799.

HIValg program. HIV Drug Resistance Database, Stanford University, Stanford. (Accessed 4 February 2014.) Available from http://sierra2.stanford.edu/sierra/servlet/JSierra?action=hivalgs.

De Luca A. , Cingolani A. , Di Giambenedetto S. Variable prediction of antiretroviral treatment outcome by different systems for interpreting genotypic human immunodeficiency virus type 1 drug resistance. J Infect Dis 2003; 187: 1934–1943.

Cysique L.A. , Maruff P. , Brew B.J. Prevalence and pattern of neuropsychological impairment in human immunodeficiency virus-infected/acquired immunodeficiency syndrome (HIV/AIDS) patients across pre- and post-highly active antiretroviral therapy eras: a combined study of two cohorts. J Neurovirol 2004; 10: 350–357.

Cysique L.A. , Maruff P. , Brew B.J. Antiretroviral therapy in HIV infection: are neurologically active drugs important? Arch Neurol 2004; 61: 1699–1704.

Cysique L.A. , Brew B.J. Prevalence of non-confounded HIV-associated neurocognitive impairment in the context of plasma HIV RNA suppression. J Neurovirol 2011; 17: 176–183.

Heaton R.K. , Clifford D.B. , Franklin D.R. Jr. HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study. Neurology 2010; 75: 2087–2096.

Bergroth T. , Ekici H. , Gisslén M. , Hagberg L. , Sönnerborg A. Difference in drug resistance patterns between minor HIV-1 populations in cerebrospinal fluid and plasma. HIV Med 2009; 10: 111–115.

Bierhoff M. , Boucher C.A. , Fibriani A. , Ten Kate R.W. Ongoing HIV replication in cerebrospinal fluid under successful monotherapy. Antivir Ther 2013; 18: 641–643.